Tag:
MM-398
Latest Headlines
Latest Headlines
Merrimack Pharma stumbles out of the IPO gate
Merrimack's shares fell 13.7% from the opening price of $7 per share, giving the developer of cancer drugs a lackluster public debut.
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- T cells 'hunt' parasites like animal predators seek prey, study shows
- UC San Diego Researchers Receive New CIRM Funding
- Same gene that stunts infants' growth also makes them grow too big
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- More Press Releases
Featured Jobs
-
Supervisor, QC Chemistry - 3rd Shift Job
Celgene Corporation - Phoenix, AZ, US -
Process Development Scientist - Downstream Job
Yoh - Durham, NC, USA -
Senior Manager, API Development
TESARO - Waltham, MA -
Senior Scientist - Permanent Job
Yoh - Doylestown, PA, USA -
Regulatory Scientist Assistant III (Senior) Job
Yoh - Kenilworth, NJ, USA
